A Supramolecular Biosensor for Rapid and High-Throughput Quantification of a Disease-Associated Niacin Metabolite
Masaya Ueno,Hiroki Sugiyama,Feng Li,Tatsuya Nishimura,Hiroshi Arakawa,Xi Chen,Xiaoxiao Cheng,Shinji Takeuchi,Yumie Takeshita,Toshinari Takamura,Sakae Miyagi,Tadashi Toyama,Tomoyoshi Soga,Yusuke Masuo,Yukio Kato,Hiroyuki Nakamura,Hiromasa Tsujiguchi,Akinori Hara,Atsushi Tajima,Moeko Noguchi-Shinohara,Kenjiro Ono,Kenta Kurayoshi,Masahiko Kobayashi,Yuko Tadokoro,Atsuko Kasahara,Mahmoud I Shoulkamy,Katsuhiro Maeda,Tomoki Ogoshi,Atsushi Hirao
DOI: https://doi.org/10.1021/acs.analchem.4c02653
2024-08-25
Abstract:Metabolic abnormalities play a pivotal role in various pathological conditions, necessitating the quantification of specific metabolites for diagnosis. While mass spectrometry remains the primary method for metabolite measurement, its limited throughput underscores the need for biosensors capable of rapid detection. Previously, we reported that pillar[6]arene with 12 carboxylate groups (P6AC) forms host-guest complexes with 1-methylnicotinamide (1-MNA), which is produced in vivo by nicotinamide N-methyltransferase (NNMT). P6AC acts as a biosensor by measuring the fluorescence quenching caused by photoinduced electron transfer upon 1-MNA binding. However, the low sensitivity of P6AC makes it impractical for detecting 1-MNA in unpurified biological samples. In this study, we found that P6A with 12 sulfonate groups (P6AS) is a specific and potent supramolecular host for 1-MNA interactions even in biological samples. The 1-MNA binding affinity of P6AS in water was found to be (5.68 ± 1.02) × 106 M-1, which is approximately 700-fold higher than that of P6AC. Moreover, the 1-MNA detection limit of P6AS was determined to be 2.84 × 10-7 M, which is substantially lower than that of P6AC. Direct addition of P6AS to culture medium was sufficient to quantify 1-MNA produced by cancer cells. Furthermore, this sensor was able to specifically detect 1-MNA even in unpurified human urine. P6AS therefore enables rapid and high-throughput quantification of 1-MNA, and further improvement of our strategy will contribute to the establishment of high-throughput screening of NNMT inhibitors, diagnosis of liver diseases, and imaging of human cancer cells in vivo.